Cited 18 times in
Efficacy of Sorafenib Monotherapy versus Sorafenib-Based Loco-Regional Treatments in Advanced Hepatocellular Carcinoma
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김범경 | - |
dc.contributor.author | 김승업 | - |
dc.contributor.author | 박예현 | - |
dc.contributor.author | 박준용 | - |
dc.contributor.author | 안상훈 | - |
dc.contributor.author | 이상헌 | - |
dc.contributor.author | 장수연 | - |
dc.contributor.author | 한광협 | - |
dc.contributor.author | 김도영 | - |
dc.date.accessioned | 2014-12-18T09:36:44Z | - |
dc.date.available | 2014-12-18T09:36:44Z | - |
dc.date.issued | 2013 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/88497 | - |
dc.description.abstract | BACKGROUND: Although sorafenib is accepted as the standard of care in advanced hepatocellular carcinoma (HCC), its therapeutic benefit is marginal. Here, we aimed to compare the efficacy and safety of sorafenib monotherapy (S-M) and sorafenib-based loco-regional treatments (S-LRTs) in advanced HCC. METHODS: From 2007 to 2012, 290 patients with advanced HCC (Barcelona Clinic Liver Cancer stage C) with S-M (n = 226) or S-LRTs (n = 64) were reviewed retrospectively. Survival outcomes and treatment-related toxicities between two groups were analyzed. RESULTS: Variables related to tumor burden and liver function were similar between the groups (all P > 0.05). Within the entire population, the S-LRTs group had both longer median overall survival (OS) (8.5 vs 5.5 months, P = 0.001) and progression-free survival (PFS) (5.3 vs 3.0 months, P = 0.002) than the S-M group. Furthermore, the S-LRTs group had longer Os than the S-M group in a subgroup with neither extrahepatic spread (EHS) nor regional nodal involvement (RNI) (18.0 vs 7.8 months, P = 0.019) and in a subgroup with EHS and/or RNI (8.3 vs 4.8 months, P = 0.028). In addition, the S-LRTs group had longer PFS than the S-M group in the subgroup with neither EHS nor RNI (9.6 vs 3.2 months, P = 0.027). TREATMENT: Related toxicity was similar between two groups. CONCLUSION: Combined use of sorafenib and LRTs may provide better treatment outcomes without significantly increasing treatment-related toxicities, even in patients with EHS and/or RNI. Therefore, addition of active LRTs might be considered, if feasible. | - |
dc.description.statementOfResponsibility | open | - |
dc.relation.isPartOf | PLOS ONE | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Carcinoma, Hepatocellular/drug therapy* | - |
dc.subject.MESH | Carcinoma, Hepatocellular/pathology* | - |
dc.subject.MESH | Cohort Studies | - |
dc.subject.MESH | Disease-Free Survival | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Kaplan-Meier Estimate | - |
dc.subject.MESH | Liver Neoplasms/drug therapy* | - |
dc.subject.MESH | Liver Neoplasms/pathology* | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Multivariate Analysis | - |
dc.subject.MESH | Neoplasm Metastasis | - |
dc.subject.MESH | Neoplasm Staging | - |
dc.subject.MESH | Niacinamide/analogs & derivatives* | - |
dc.subject.MESH | Niacinamide/therapeutic use | - |
dc.subject.MESH | Phenylurea Compounds/therapeutic use* | - |
dc.subject.MESH | Treatment Outcome | - |
dc.subject.MESH | alpha-Fetoproteins/metabolism | - |
dc.title | Efficacy of Sorafenib Monotherapy versus Sorafenib-Based Loco-Regional Treatments in Advanced Hepatocellular Carcinoma | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학) | - |
dc.contributor.googleauthor | Sangheun Lee | - |
dc.contributor.googleauthor | Beom Kyung Kim | - |
dc.contributor.googleauthor | Seung Up Kim | - |
dc.contributor.googleauthor | Yehyun Park | - |
dc.contributor.googleauthor | Sooyun Chang | - |
dc.contributor.googleauthor | Jun Yong Park | - |
dc.contributor.googleauthor | Do Young Kim | - |
dc.contributor.googleauthor | Sang Hoon Ahn | - |
dc.contributor.googleauthor | Chae Yoon Chon | - |
dc.contributor.googleauthor | Kwang-Hyub Han | - |
dc.identifier.doi | 10.1371/journal.pone.0077240 | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A00487 | - |
dc.contributor.localId | A00654 | - |
dc.contributor.localId | A01575 | - |
dc.contributor.localId | A01675 | - |
dc.contributor.localId | A02226 | - |
dc.contributor.localId | A02834 | - |
dc.contributor.localId | A03443 | - |
dc.contributor.localId | A04268 | - |
dc.contributor.localId | A00385 | - |
dc.relation.journalcode | J02540 | - |
dc.identifier.eissn | 1932-6203 | - |
dc.identifier.pmid | 24155932 | - |
dc.subject.keyword | Carcinoma, Hepatocellular/drug therapy* | - |
dc.subject.keyword | Carcinoma, Hepatocellular/pathology* | - |
dc.subject.keyword | Cohort Studies | - |
dc.subject.keyword | Disease-Free Survival | - |
dc.subject.keyword | Female | - |
dc.subject.keyword | Humans | - |
dc.subject.keyword | Kaplan-Meier Estimate | - |
dc.subject.keyword | Liver Neoplasms/drug therapy* | - |
dc.subject.keyword | Liver Neoplasms/pathology* | - |
dc.subject.keyword | Male | - |
dc.subject.keyword | Middle Aged | - |
dc.subject.keyword | Multivariate Analysis | - |
dc.subject.keyword | Neoplasm Metastasis | - |
dc.subject.keyword | Neoplasm Staging | - |
dc.subject.keyword | Niacinamide/analogs & derivatives* | - |
dc.subject.keyword | Niacinamide/therapeutic use | - |
dc.subject.keyword | Phenylurea Compounds/therapeutic use* | - |
dc.subject.keyword | Treatment Outcome | - |
dc.subject.keyword | alpha-Fetoproteins/metabolism | - |
dc.contributor.alternativeName | Kim, Beom Kyung | - |
dc.contributor.alternativeName | Kim, Seung Up | - |
dc.contributor.alternativeName | Park, Ye Hyun | - |
dc.contributor.alternativeName | Park, Jun Yong | - |
dc.contributor.alternativeName | Ahn, Sang Hoon | - |
dc.contributor.alternativeName | Lee, Sang Heun | - |
dc.contributor.alternativeName | Chang, Soo Yun | - |
dc.contributor.alternativeName | Han, Kwang Hyup | - |
dc.contributor.alternativeName | Kim, Do Young | - |
dc.contributor.affiliatedAuthor | Kim, Beom Kyung | - |
dc.contributor.affiliatedAuthor | Kim, Seung Up | - |
dc.contributor.affiliatedAuthor | Park, Ye Hyun | - |
dc.contributor.affiliatedAuthor | Park, Jun Yong | - |
dc.contributor.affiliatedAuthor | Ahn, Sang Hoon | - |
dc.contributor.affiliatedAuthor | Lee, Sang Heun | - |
dc.contributor.affiliatedAuthor | Chang, Soo Yun | - |
dc.contributor.affiliatedAuthor | Han, Kwang Hyup | - |
dc.contributor.affiliatedAuthor | Kim, Do Young | - |
dc.rights.accessRights | free | - |
dc.citation.volume | 8 | - |
dc.citation.number | 10 | - |
dc.citation.startPage | e77240 | - |
dc.identifier.bibliographicCitation | PLOS ONE, Vol.8(10) : e77240, 2013 | - |
dc.identifier.rimsid | 34064 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.